AstraZeneca Results Presentation Deck

Core profit and loss Total revenue - product sales - collaboration revenue Gross margin Operating expenses - R&D expenses - SG&A expenses Other operating income Operating profit Tax rate EPS FY 2020 $m 26,617 25,890 727 80.0% 15,633 5,872 9,362 1,531 7,340 20.1% $4.02 change % 10 11 (11) 0.3 pp 6 10 4 (2) 17 18 % total revenue 100 97 3 59 22 35 6 28 Q4 2020 $m 7,410 7,011 399 78.6% 4,654 1,707 2,838 642 1,899 17.6% $1.07 Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of product sales. 21 change % 10 11 (4) 2.0 pp 8 12 6 29 28 24 % total revenue 100 95 5 63 23 38 9 26 3

View entire presentation